de Vries F, van Staa T P, Bracke M S G M, Cooper C, Leufkens H G M, Lammers J-W J
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, The Netherlands.
Eur Respir J. 2005 May;25(5):879-84. doi: 10.1183/09031936.05.00058204.
The use of inhaled corticosteroids has been associated with a dose-related increased risk of fracture. This may be related to systemic absorption. However, several studies have found that patients with more severe reductions in pulmonary function had reduced bone mineral density, independent of inhaled corticosteroids. The objective of this study was to evaluate the relationship between disease severity and fracture risk. A large case-control study (108,754 cases) was conducted using data from the UK General Practice Research Database. It was found that higher doses of inhaled corticosteroids were associated with greater risks of fracture. The crude odds ratio of fracture among patients exposed to >1,600 microg beclomethasone equivalents per day was 1.95 (95% confidence interval (CI) 1.68-2.27). When adjustments were made for disease severity and use of bronchodilators, the initial dose-response relationship between inhaled corticosteroids and fracture risk disappeared (adjusted odds ratio of 1.19 (95% CI 1.01-1.41)). In conclusion, patients with severe obstructive airway disease are at risk of fracture. However, adequate adjustment for disease severity is essential when the association between the use of inhaled corticosteroids and risk of osteoporotic fracture is studied in observational research.
吸入性糖皮质激素的使用与骨折风险呈剂量相关的增加。这可能与全身吸收有关。然而,几项研究发现,肺功能严重下降的患者骨密度降低,与吸入性糖皮质激素无关。本研究的目的是评估疾病严重程度与骨折风险之间的关系。利用英国全科医疗研究数据库的数据进行了一项大型病例对照研究(108,754例)。结果发现,更高剂量的吸入性糖皮质激素与更高的骨折风险相关。每天暴露于>1600微克倍氯米松等效物的患者骨折的粗比值比为1.95(95%置信区间(CI)1.68 - 2.27)。当对疾病严重程度和支气管扩张剂的使用进行调整后,吸入性糖皮质激素与骨折风险之间最初的剂量反应关系消失(调整后的比值比为1.19(95%CI 1.01 - 1.41))。总之,重度阻塞性气道疾病患者有骨折风险。然而,在观察性研究中研究吸入性糖皮质激素的使用与骨质疏松性骨折风险之间的关联时,对疾病严重程度进行充分调整至关重要。